Last year’s Tang Prize laureates for biopharmaceutical science on Saturday reflected on the challenges faced and breakthroughs in their research related to cytokines that has helped many people fight inflammatory diseases.
Continuing the series of lectures delivered by last year’s winners, American Charles Dinarello, Marc Feldmann of the UK and Tadamitsu Kishimoto of Japan offered glimpses of how the understanding of cytokines has evolved and its effect on human health.
Cykotines are proteins produced by the immune system that transmit messages to various cells in the body and are contributors to inflammatory diseases, autoimmune syndromes and cancers, roles that the three immunologists have helped uncover and counter.
Photo: CNA
Dinarello, 78, is considered “one of the founders” of cytokines for his work in identifying the cytokine interleukin-1 (IL-1) and its role in causing fever and inflammation, despite initial skepticism in the scientific community.
Dinarello said the discovery of IL-1 alpha and IL-1 beta, two fever-producing molecules, “was an important step in the history of cytokine biology.”
After early experiments in humans, “the history of cytokines being used as a treatment changed dramatically,” because it was clear IL-1 overproduction was a common cause of many diseases, Dinarello said.
The focus then shifted to “inhibiting cytokines, such as IL-1, such as TNF, such as IL-6,” he said, which led to the development of many therapies, including some based on the interleukin-1 receptor antagonist (IL-1Ra) protein.
IL-1Ra can inhibit IL-1 alpha and beta, and block interleukin-1 receptor (IL-1R) signaling, and Anakinra, a recombinant form of IL-1Ra, is now used to treat rheumatoid arthritis and prevent glycemic disorders in type 2 diabetes, he said.
Then there is canakinumab, an anti-IL-1 beta monoclonal antibody, that has been approved for treating a variety of diseases and could have a role in treating cancer, based on a clinical trial, he said.
Feldmann, 76, is known for identifying tumor necrosis factor (TNF) as the critical cytokine in rheumatoid arthritis and then developing therapies that combat TNF.
He said that roughly 50 percent of rheumatoid arthritis patients responded to anti-TNF therapy and the cancer drug methotrexate, but added that “we’ve got a long way to go before every patient is cured.”
TNF poses a challenge because TNF receptor-1 drives inflammation while receptor-2 does the opposite, meaning that if you block TNF entirely, you may be both blocking inflammation and preventing the body from dampening down the inflammation, he said.
He and his colleagues are now “generating tools” that block TNFR1 without changing the function of regulatory T cells, he said.
Kishimoto, 82, is best known for his discovery and cloning of a cytokine, later named interleukin-6 (IL-6), that also contributes to the development of various inflammatory diseases.
In his talk, Kishimoto looked back at the research he and his team have carried out on IL-6 over the past 50 years, including how it was discovered and how it even ended up being relevant for treating COVID-19 patients.
“We discovered the overproduction of IL-6 has been found to be associated with many diseases, such as cardiac myxoma, Castleman’s disease, rheumatoid arthritis and systemic onset of juvenile idiopathic arthritis [JIA],” Kishimoto said.
To tackle the inflammatory responses provoked by IL-6 overproduction, Kishimoto and his team tried to treat patients by blocking IL-6 signals, and subsequently developed tocilizumab, an anti-IL-6 receptor monoclonal antibody.
It has since been approved for use in more than 100 countries for the treatment of rheumatoid arthritis and JIA, and also has proven effective in battling cytokine storms.
Kishimoto and his team believed that tocilizumab could be effective in helping seriously-ill COVID-19 patients deal with cytokine storms, and large-scale clinical trials proved it could reduce the need for invasive ventilation or the risk of death.
The US Food and Drug Administration and the WHO have issued emergency use authorizations for tocilizumab for the treatment of COVID-19 patients, Kishimoto said.
The three lectures were aired on the Tang Prize YouTube channel on Saturday.
Twenty-four Republican members of the US House of Representatives yesterday introduced a concurrent resolution calling on the US government to abolish the “one China” policy and restore formal diplomatic relations with Taiwan. Led by US representatives Tom Tiffany and Scott Perry, the resolution calls for not only re-establishing formal relations, but also urges the US Trade Representative to negotiate a free-trade agreement (FTA) with Taiwan and for US officials to advocate for Taiwan’s full membership in the UN and other international organizations. In a news release announcing the resolution, Tiffany, who represents a Wisconsin district, called the “one China” policy “outdated, counterproductive
Actress Barbie Hsu (徐熙媛) has “returned home” to Taiwan, and there are no plans to hold a funeral for the TV star who died in Japan from influenza- induced pneumonia, her family said in a statement Wednesday night. The statement was released after local media outlets reported that Barbie Hsu’s ashes were brought back Taiwan on board a private jet, which arrived at Taipei Songshan Airport around 3 p.m. on Wednesday. To the reporters waiting at the airport, the statement issued by the family read “[we] appreciate friends working in the media for waiting in the cold weather.” “She has safely returned home.
ON PAROLE: The 73-year-old suspect has a criminal record of rape committed when he was serving in the military, as well as robbery and theft, police said The Kaohsiung District Court yesterday approved the detention of a 73-year-old man for allegedly murdering three women. The suspect, surnamed Chang (張), was arrested on Wednesday evening in connection with the death of a 71-year-old woman surnamed Chao (趙). The Kaohsiung City Police Department yesterday also unveiled the identities of two other possible victims in the serial killing case, a 75-year-old woman surnamed Huang (黃), the suspect’s sister-in-law, and a 75-year-old woman surnamed Chang (張), who is not related to the suspect. The case came to light when Chao disappeared after taking the suspect back to his residence on Sunday. Police, upon reviewing CCTV
TRUMP ERA: The change has sparked speculation on whether it was related to the new US president’s plan to dismiss more than 1,000 Joe Biden-era appointees The US government has declined to comment on a post that indicated the departure of Laura Rosenberger as chair of the American Institute in Taiwan (AIT). Neither the US Department of State nor the AIT has responded to the Central News Agency’s questions on the matter, after Rosenberger was listed as a former chair on the AIT’s official Web site, with her tenure marked as 2023 to this year. US officials have said previously that they usually do not comment on personnel changes within the government. Rosenberger was appointed head of the AIT in 2023, during the administration of former US president Joe